Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In double-blind, placebo-controlled trials, budesonide-formoterol used on an as-needed basis resulted in a lower risk of severe exacerbation of asthma than as-needed use of a short-acting β2-agonist (SABA); the risk was similar to that of budesonide maintenance therapy plus as-needed SABA. The availability of data from clinical trials designed to better reflect clinical practice would be beneficial.

Related collections

Author and article information

Journal

Title: New England Journal of Medicine

Abbreviated Title: N Engl J Med

Publisher: Massachusetts Medical Society

ISSN (Print): 0028-4793

ISSN (Electronic): 1533-4406

Publication date Created: May 19 2019

Publication date (Electronic): May 19 2019

Affiliations

[1 ]From the Medical Research Institute of New Zealand (R.B., M.H., I.B., S.E., C.H., K.O., M. Williams), the Capital and Coast District Health Board (R.B.), and the University of Otago Wellington (M. Weatherall), Wellington, the Department of Respiratory Medicine, Waikato Hospital, Hamilton (R.J.H.), and the Department of Preventive and Social Medicine, University of Otago, Dunedin (R.J.H.) — all in New Zealand; Woolcock Institute of Medical Research, University of Sydney, Sydney (H.K.R.); the Nottingham...

Article

DOI: 10.1056/NEJMoa1901963

PubMed ID: 31112386

SO-VID: cc7c3211-d6e3-4bb5-ae95-cdf0f24b2871

License:

http://www.nejmgroup.org/legal/terms-of-use.htm

History

Data availability:

Comments

Comment on this article

scite_

Cited by 129

See all cited by

- Version 1